Galectin Therapeutics (GALT) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.54% |
| Dec 31, 2025 | -2.41% |
| Sep 30, 2025 | 15.68% |
| Jun 30, 2025 | -20.48% |
| Mar 31, 2025 | -11.96% |
| Dec 31, 2024 | -27.70% |
| Sep 30, 2024 | -42.15% |
| Jun 30, 2024 | -29.03% |
| Mar 31, 2024 | -29.81% |
| Dec 31, 2023 | -18.74% |
| Sep 30, 2023 | -37.09% |
| Jun 30, 2023 | -26.14% |
| Mar 31, 2023 | -25.15% |
| Dec 31, 2022 | -13.14% |
| Sep 30, 2022 | -21.73% |
| Jun 30, 2022 | -8.23% |
| Mar 31, 2022 | -15.79% |
| Dec 31, 2021 | -7.40% |
| Sep 30, 2021 | -7.73% |
| Jun 30, 2021 | -5.33% |
| Mar 31, 2021 | -12.83% |
| Dec 31, 2020 | -3.31% |
| Sep 30, 2020 | -10.06% |
| Jun 30, 2020 | 2.71% |
| Mar 31, 2020 | -0.28% |
| Dec 31, 2019 | -3.84% |
| Sep 30, 2019 | 14.78% |
| Jun 30, 2019 | 0.69% |
| Mar 31, 2019 | 1.92% |
| Dec 31, 2018 | -4.05% |
| Sep 30, 2018 | -1.24% |
| Jun 30, 2018 | -9.77% |
| Mar 31, 2018 | -7.73% |
| Dec 31, 2017 | -17.39% |
| Sep 30, 2017 | -8.48% |
| Jun 30, 2017 | -18.03% |
| Mar 31, 2017 | -21.05% |
| Dec 31, 2016 | -25.83% |
| Sep 30, 2016 | -22.45% |
| Jun 30, 2016 | -24.91% |
| Mar 31, 2016 | -20.62% |
| Dec 31, 2015 | -51.16% |
| Sep 30, 2015 | -43.79% |